Sur180 Therapeutics, INC

Sur180 Therapeutics is changing the way endometriosis pain and progression are treated. We are re-introducing drugs tested for safety but never commercialized for their original intent. While all current endometriosis therapies target the gonadal system, we focus on the stress system, which has intimate crosstalk with female gonads. The company is strongly positioned to decrease chronic pelvic pain and endometriosis recurrence, resulting in millions of dollars in savings associated with repeated surgeries and productivity loss in women with endometriosis. Sur180 Therapeutics plans to use a direct-to-Phase II approach for testing our drug against endometriosis.